BiondVax Pharmaceuticals Ltd. Stock Price, News & Analysis

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) announced an investor webinar scheduled for April 6, 2022, conducted in Hebrew. CEO Amir Reichman will cover key updates, including the collaboration on the nanosized antibody (NanoAb) pipeline with Max Planck Institute and University Medical Center Göttingen, manufacturing progress in Jerusalem, and negotiations with the European Investment Bank. The webinar will include a Q&A session, time permitting. A prior English-language webinar on NanoAb research is also accessible online.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced a webinar for analysts and investors on April 4, 2022, at 10 am (ET). CEO Amir Reichman will discuss the development of their nanosized antibody (NanoAb) pipeline, collaboration with Max Planck Institute, and fiscal year 2021 financial results. Professor Matthias Dobbelstein will share insights on NanoAb research. Registration for the webinar is available here.

BiondVax Pharmaceuticals (NASDAQ: BVXV) reported its financial results for Q4 and the full year 2021, highlighting a strategic turnaround and promising developments. Total operating expenses fell to NIS 34.8 million ($11.2 million) in 2021, significantly down from NIS 68.8 million in 2020. The company signed exclusive licensing agreements for COVID-19 NanoAbs and initiated in-house manufacturing, enhancing control over its product pipeline. As of December 31, 2021, cash and cash equivalents increased to NIS 54 million ($17.4 million) due to successful share offerings.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) has formed a strategic collaboration with the Max Planck Society and University Medical Center Göttingen to develop innovative nanosized antibodies (NanoAbs). BiondVax has secured exclusive worldwide licensing rights for these therapies, which target diseases with significant market potential, including psoriasis and COVID-19. Initial preclinical results are expected in 2023. The NanoAb platform promises advantages like strong binding affinity and stability, and is supported by BiondVax's advanced manufacturing capabilities in Jerusalem.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced a preliminary agreement with the European Investment Bank (EIB) to restructure a €24 million loan, extending its maturity until December 2027. The restructuring includes deferred interest payments starting January 1, 2022, and a principal reduction of $900,000. Additionally, once commercial sales exceed €5 million, 3% of revenues will be paid to EIB as royalties. CEO Amir Reichman expressed optimism about the support from EIB, emphasizing its role in advancing BiondVax's innovative antibody pipeline.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced its participation in the Aegis Capital Corp. Virtual Conference on February 23, 2022, at 9:30am ET. The presentation will highlight the development of innovative nanosized antibodies (NanoAbs) that offer competitive advantages in treating infectious diseases. The presentation will be accessible to Aegis attendees from February 23 to 25 and will also be available on BiondVax's website. The company has conducted eight clinical trials and is focused on developing a diverse pipeline of biopharmaceutical products.

BiondVax Pharmaceuticals (Nasdaq: BVXV) has announced that CEO Amir Reichman will present at the BIO CEO & Investor Conference from February 15, 2022. His presentation highlights a new collaboration aimed at developing innovative therapeutic NanoAbs. Participants can access the presentation on-demand through the conference portal or BiondVax's website. The company is also set to hold virtual meetings with investors during the conference.

BiondVax, established to combat infectious diseases, has conducted several clinical trials and aims to expand its portfolio of therapeutic options.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced its presentation at the Edison Open House: Global Healthcare 2022 conference on January 26, 2022. The presentation is available on-demand via the conference portal. Management will also hold virtual 1-1 meetings with investors regarding this event. BiondVax focuses on developing innovative biopharmaceutical products for infectious diseases and has conducted multiple clinical trials, including a significant Phase 3 trial with 12,400 participants. For additional details, visit www.biondvax.com.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced its participation in the H.C. Wainwright Bioconnect Virtual Conference from January 10 to 13, 2022. The company will present an overview, and the presentation will be available on-demand for registered attendees. Additionally, a slide deck will be accessible on BiondVax's website. The company focuses on developing innovative products for infectious diseases, including a nanosized antibody pipeline and has completed eight clinical trials, demonstrating a commitment to diverse and commercially viable therapeutic options.